Quarter

Canada prepares to welcome the world to the UN Conference of the Parties on Biological Diversity: COP15

Retrieved on: 
Thursday, December 1, 2022

In a global effort to halt and reverse biodiversity loss, Canada is welcoming the world to Montral this month for the 15th Conference of the Parties to the United Nations Convention on Biological Diversity (COP15).

Key Points: 
  • In a global effort to halt and reverse biodiversity loss, Canada is welcoming the world to Montral this month for the 15th Conference of the Parties to the United Nations Convention on Biological Diversity (COP15).
  • This landmark international nature conference, the largest in a generation, will see thousands of delegates from around the world gathered in Montral to take action on protecting nature.
  • Today, a flag-raising ceremony took place outside the conference venue, symbolizing the hand-over of the space to the United Nations Convention on Biological Diversity.
  • Visual arts: The Canada Council for the Arts will present a thematic display of 40 works of art from its Art Bank collection to COP15 delegates.

Hamilton Thorne Announces the Acquisition of Microptic, S.L.

Retrieved on: 
Thursday, December 1, 2022

BEVERLY, Mass. and TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies ("ART") research, and cell biology markets, today announced that it has closed the acquisition (the "Transaction") of Microptic, S.L. ("Microptic") effective as of November 30, 2022.

Key Points: 
  • The Transaction expands Hamilton Thorne's product offerings and provides the Company with profitable operations in the well-established European ART market.
  • Key Benefits of the Transaction:
    "We are excited to welcome our new partners from Microptic to the Hamilton Thorne family.
  • This acquisition enhances our product offerings in AI enabled CASA software, image analysis systems, consumables, and related products.
  • Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event brands, and Microptic, through its growing sales force and distributors worldwide.

Humble & Fume Inc. Announces Financial Results for First Quarter Fiscal 2023

Retrieved on: 
Tuesday, November 29, 2022

Joel Toguri, Chief Executive Officer of Humble, commented:

Key Points: 
  • Joel Toguri, Chief Executive Officer of Humble, commented:
    "Our focus continues to be optimizing growth opportunities while proactively right-sizing the business.
  • Restructuring initiatives completed last fiscal year are positively impacting the P&L, with operational expenses relating to the North American accessories down quarter-over-quarter by $3.8m or 44%.
  • Year over year inventory has decreased by $6.5m, with the prior year having a balance of $17.8m vs the current balance of $11.2m.
  • Statements about, among other things, Humble & Fume Inc.'s strategic plans including future growth opportunities and strategies in the United States are all forward-looking information.

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Retrieved on: 
Tuesday, November 29, 2022

WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.

Key Points: 
  • WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.
  • Research & development costs increased by approximately $0.2 million, or approximately 15%, from approximately $1.3 million in the Fiscal 2022 Quarter, to approximately $1.5 million in the Fiscal 2023 Quarter.
  • Additionally, the Company incurred payroll-related expenses of $0.5 million in Fiscal 2023 Quarter, compared to $0.2 million in the Fiscal 2022 Quarter.
  • General and administrative expenses increased by approximately $0.1 million, or approximately 5%, from approximately $2.0 million in the Fiscal 2022 Quarter, to approximately $2.1 million in the Fiscal 2023 Quarter.

Cansortium Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 29, 2022

- Q3 Adjusted EBITDA up 15% QoQ and More Than 2x YoY to a Record $11.7 Million, with $5.4 Million of Cash from Operations -

Key Points: 
  • - Q3 Adjusted EBITDA up 15% QoQ and More Than 2x YoY to a Record $11.7 Million, with $5.4 Million of Cash from Operations -
    MIAMI, Nov. 29, 2022 /PRNewswire/ - Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating under the Fluent brand, today announced financial and operating results for the third quarter ended September 30, 2022.
  • Q3 2022 Financial Highlights (vs. Q3 2021)
    Revenue increased 42% to $22.1 million compared to $15.6 million.
  • During the third quarter, Cansortium temporarily closed twelve of its dispensaries in Florida during Hurricane Ian.
  • Cansortium now expects revenue for 2022 to range between $85-$90 million (previously expected $90-$95 million).

Genetec's Q2FY2023 Performance Remains on Track

Retrieved on: 
Tuesday, November 29, 2022

Earnings per share stood at 3.59 sen (fully diluted) in the same quarter compared to EPS of 2.33 sen in the corresponding quarter.

Key Points: 
  • Earnings per share stood at 3.59 sen (fully diluted) in the same quarter compared to EPS of 2.33 sen in the corresponding quarter.
  • We have been building on our momentum and diversifying our portfolio in electric vehicle (EV) and energy storage segments.
  • Genetec remains focused to build on and deepen our share-of-wallet with existing clients.
  • On the EV sector, we will continue to expand our performance and increase our capacity to achieve new heights", highlighted Genetec.

Yalla Group Q3 Earnings: Quarterly revenue passes US$ 80 million as steady growth continues

Retrieved on: 
Monday, November 28, 2022

The results highlighted that Yalla had surpassed revenue expectations during the quarter and maintained its steady growth.

Key Points: 
  • The results highlighted that Yalla had surpassed revenue expectations during the quarter and maintained its steady growth.
  • Yalla's revenues were US$ 80.1 million in Q3 2022, representing a YoY increase of 12.3% and a QoQ increase of 5.2%.
  • In Q3 2022, the non-GAAP net income was US$ 29.4 million, representing a YoY decrease of 11.5% and a QoQ increase of 2.7%.
  • In Q3, Yalla launched distribution gift cards for Yalla Ludo on its marketing channels, which improved the monetization of products.

EQS-News: AmeraMex International Reports Financial Results for Its Third Quarter Ended September 30, 2022

Retrieved on: 
Sunday, November 27, 2022

AmeraMex International, Inc. (OTCQB:AMMX), a provider of heavy equipment for logistics companies , infrastructure construction , and forestry conservation , reported financial results for its third quarter ended September 30, 2022.

Key Points: 
  • AmeraMex International, Inc. (OTCQB:AMMX), a provider of heavy equipment for logistics companies , infrastructure construction , and forestry conservation , reported financial results for its third quarter ended September 30, 2022.
  • If you have questions regarding the third quarter results, please contact CFO, Hope Stone, or board member, Marty Tullio, added Hamre.
  • Gross profit for the quarter was $2.5 million, compared to gross profit of $815,261 for the comparable 2021 quarter.
  • Earnings per share (EPS) were $0.06 for the quarter compared to EPS of $0.01 for the comparable 2021 quarter.

20e Guignolée Dr Julien - La Fondation Dr Julien lance un appel à la générosité pour garantir aux enfants vulnérables un avenir en santé

Retrieved on: 
Wednesday, November 16, 2022

Montral, Nov. 16, 2022 (GLOBE NEWSWIRE) -- La Fondation Dr Julien lance la 20edition de la Guignole Dr Julien au profit de la pdiatrie sociale en communaut, un modle de mdecine sociale qui permet aux enfants issus de milieux dfavoriss de grandir en sant.

Key Points: 
  • Montral, Nov. 16, 2022 (GLOBE NEWSWIRE) -- La Fondation Dr Julien lance la 20edition de la Guignole Dr Julien au profit de la pdiatrie sociale en communaut, un modle de mdecine sociale qui permet aux enfants issus de milieux dfavoriss de grandir en sant.
  • Grandir dans ces conditions entraine des consquences dltres sur leur sant mentale et cognitive, en plus de compromettre leur avenir.
  • Donnez la Guignole Dr Julien , dclare le Dr Gilles Julien, pionnier de la pdiatrie sociale en communaut, fondateur et vice-prsident de la fondation qui porte son nom.
  • Cette richesse, le quartier la doit en grande partie au Dr Gilles Julien et la pdiatrie sociale en communaut, explique-t-elle.

Cool Company Ltd. Q3 2022 Business Update

Retrieved on: 
Wednesday, November 16, 2022

Due to idle days prior to the September delivery of the $140,000 per day re-contracted vessel, Q3 2022 fleet utilization was 95%.

Key Points: 
  • Due to idle days prior to the September delivery of the $140,000 per day re-contracted vessel, Q3 2022 fleet utilization was 95%.
  • As of September 30, 2022, CoolCo had cash and cash equivalents of $94.8 million and total short and long-term debt of $657.4 million.
  • Of these, EPS hold 26,790,545 shares, equivalent to approximately 49.9% of the Company, Golar holds 4,463,846 shares, equivalent to approximately 8.3% of the Company and the public holds 22,434,071 shares, equivalent to approximately 41.8% of the Company.
  • The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.